LLYELI LILLY & Co
Pharmaceutical Preparations
- Revenue
- $65.2B
- 45% YoY
- Operating margin
- —
- EBITDA
- —
- Market cap
- $1.3T
- Employees
- 200,000
- $326K revenue each
- Net debt / EBITDA
- —
- $37.6B net debt
- AI in 10-K
- 4.0
- mentions per 10K words
Takeover score 1 of 13
Fixable underperformance 0 of 7
- TSR below peersNo—3+ of last 5 years
- High CEO pay despite TSRNo—Median CEO pay ≥ $15M while TSR trails
- Earnings not backed by cashNo81% of net incomeCash flow under 80% of net income
- Dilutive SBCNo1% of revenueOver 10% of revenue
- Payouts exceed cash flowNo56% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyNo7% of assetsOver 40% of assets
- Shareholder dissentNo96% lowest supportAny vote under 80% support
Buyer economics 0 of 4
- Low revenue per employeeNo$326K · 45th pctBottom quartile of its SIC industry
- Quiet on AINo4.0 per 10K words · 78th pctBottom quartile of AI mentions in 10-Ks
- Net cashNo—More cash than debt, positive EBITDA
- Buyout-sizedNo$1.3T market capMarket cap $500M–$5B
Catalysts 1 of 2
- Active 13DNo0 filingsActive-intent 13D in 18 months
- Net insider sellingYes−$78.1B netNet sales over $10M in 12 months
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $28.3B | $28.5B | $34.1B | $45.0B | $65.2B | 45% |
| Net income | $5.6B | $6.2B | $5.2B | $10.6B | $20.6B | 95% |
| Operating cash flow | $7.4B | $7.6B | $4.2B | $8.8B | $16.8B | 91% |
| Stock-based comp | $343M | $371M | $629M | $646M | $626M | 3.1% |
| Buybacks | $1.3B | $1.5B | $750M | $2.5B | $4.1B | 64% |
| Dividends | $3.1B | $3.5B | $4.1B | $4.7B | $5.4B | 15% |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $0 · 0
- Open-market sells, 12 mo
- $78.1B · 240
- Net
- −$78.1B
Pay vs performance
No pay-versus-performance disclosure yet.